495Tip A Phase II Study Evaluating the Safety and Efficacy of ENV-101 (taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

J. J. Luke, S. Pendyala,A. Di Francesco, S. Kim, L. Dellamary,H. Humphreys, M. De Los Rios, J. Pitman,J. Hood,D. S. Hong

Annals of Oncology（2022）

Cited 0|Views24

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined